Skip to content
Open access

Managing Multi-Source Data in Global Oncology Trials: Operational and Data Quality Insights From the COST-FIN Trial

Nov 2026 · JCO Global Oncology · Vol 12, pp. 51-52 · 0 citations

TL;DR

Within COST- FIN, RAs, data quality oversight, and in-country project management were essential to trial operations, financial data integrity, and cross-site implementation fidelity.

Abstract

Successful implementation of global oncology clinical trials in low- and middle-income countries requires strong operational systems, including research assistants (RAs), centralized data quality oversight, and coordinated multi-site management. COST-FIN is a pragmatic randomized controlled trial evaluating whether structured financial navigation (FN) reduces financial catastrophe, financial distress, and cost-related treatment non-adherence among adults with newly diagnosed breast, colorectal, or prostate cancer in Nigeria. This analysis describes the staffing, data quality, and coordination infrastructure needed to implement COST-FIN across Nigerian oncology sites. We conducted a mixed-methods evaluation of operational experiences within COST-FIN. Seven RAs across three sites conducted screening, enrollment, and longitudinal follow-up. Data collection included structured interviews, medical record abstraction, and patient receipts, captured through electronic and paper-based systems and reconciled into a centralized database. A dedicated data quality manager oversaw validation, discrepancy resolution, and receipt-level data integration through an individual receipt submission workflow. In-country coordination was led by a Nigeria-based project manager with a U.S.-based trial coordinator. Data sources included workload logs, data quality reports, and qualitative feedback from RAs and leadership. Between July 2024 and April 2026, 1,200 patients were screened, and 220 were enrolled. The RA team supported enrollment and follow-up across multiple institutions while managing high- volume, multi-source data. Operational workload included processing and verifying more than 4,000 patient receipts, along with baseline and follow-up assessments. Over 22 months, RAs contributed an estimated 24,160 hours across enrollment, follow-up, and data management, while centralized data quality oversight required more than 500 hours. RAs integrated clinical, interview, and financial data, requiring continuous reconciliation of paper and electronic records. Centralized oversight supported systematic discrepancy resolution, data completeness, and audit readiness. The Nigeria-based project manager facilitated real-time site coordination and linked local teams with international leadership. Qualitative findings highlighted the time-intensive nature of financial data verification and the importance of layered coordination structures. Large-scale global oncology trials in resource-limited settings require sustained investment in frontline research staff, centralized data systems, and multi-level coordination. Within COST- FIN, RAs, data quality oversight, and in-country project management were essential to trial operations, financial data integrity, and cross-site implementation fidelity.

Read PDF

Similar papers

Open access Oct 2026

Improving data capture of the patient experience for young adults with cancer: A randomized controlled trial of precision electronic patient-reported outcomes in community-based oncology practices (ECOG-ACRIN EAQ202).

431 Background: Patient-reported outcomes (PROs) characterize patient perspectives on symptoms, functioning, and health-related quality of life (HRQOL). Despite rising cancer incidence among young adults (YAs), PROs are underutilized, particularly in NCI Community Oncology Research Program (NCORP) sites, where...

J. Salsman, Feng-Hai Duan, S. Dinner et al. · 0 citations
Open access Oct 2026

Rebalancing cancer care financing: Resource utilization patterns from the COST-FIN trial in Nigeria.

17 Background: In low- and middle-income countries, patients face high out-of-pocket expenses for consultations, diagnostics, chemotherapy, radiotherapy, and surgery contributing to treatment delays or discontinuation. COST-FIN is the first randomized controlled trial evaluating whether structured financial nav...

D. Ebekue, F. Wuraola, Titilope Ogunniyi et al. · 0 citations
Review Open access Oct 2026

PROGRESS: Implementing a hybrid decentralized clinical trial to advance precision oncology and improve cancer care quality and equity across North Carolina oncology practices.

70 Background: Rates of comprehensive molecular profiling (CMP), use of evidence-based genome-informed therapy (GIT), and clinical trial participation remain low despite being markers of high-quality cancer care. PROGRESS is an interventional study evaluating the impact of a centralized precision oncology navig...

Meghan McGonagle, Stephanie Drotts, Jaime Richardson et al. · 0 citations
Review Open access Nov 2026

[Value-based health care for prostate cancer centers-implementation of specific key performance indicators using a Balanced Scorecard].

BACKGROUND Prostate cancer (PC) is the most common cancer in men in Germany, accounting for 29% of all malignancies. Since it cannot be prevented, improved diagnostics and therapy are required. Within the framework of so-called value-based healthcare, the Balanced Scorecard (BSC) has been established as a measurement i...

A. Panic, Peter Albers, Isabelle Bußhoff et al. · 0 citations
Review Open access Oct 2026

Impact of an EMR-integrated, screening-based oncology financial counseling program.

350 Background: Financial hardship (FH) is highly prevalent in oncology, adversely impacting quality of life and clinical outcomes. While FH screening is increasing, translating positive screens into actionable financial navigation remains a critical care gap. This study aims to evaluate the implementation and...

Nickolas Dreher, Laura M. Jordan, Billy Mei et al. · 0 citations
Review Open access Sep 2026

Survey and Patient-Reported Outcome Measure Instruments for Assessing Out-of-Pocket Costs and Financial Toxicity in Cancer Care: A Systematic Review.

OBJECTIVES Out-of-pocket (OOP) costs and financial toxicity remain significant barriers to equitable cancer care globally. This review systematically identifies and compares survey-based approaches used to measure patient- and household-level OOP expenditures and financial burden across diverse cancer settings. METHO...

S. Foo, Jing-Sheng Lim, A. V. Thakumar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.